Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Ceribell Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Ceribell Inc (CBLL) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026
Competitors Tracked
-
Publicly traded peers
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
35.85 %
Q2 2026
Net Margin
-68.58 %
Q2 2026

Key Findings: Ceribell Inc vs Its Competitors

  • TTM: Trailing 12-month revenue of 102M vs -M combined for tracked competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is accelerating (+10.4% annualized vs trailing 12 months).
  • Scale: Ceribell Inc ranks #73 of 247 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.1% of industry market cap.
  • Peer revenue share: Ceribell Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

CBLL Sales vs. its Competitors, Q2 2026

Ceribell Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/CBLL/competitors
https://api.csimarket.com/api/v1/companies/CBLL/relationships
https://api.csimarket.com/api/v1/companies/CBLL/similar
Programmatic access for models, analytics, and integration workflows.

For context: the Medical Equipment & Supplies industry grew revenue 15.1% year over year, combined, vs 35.9% for Ceribell Inc. Ceribell Inc's share of combined industry revenue moved from 0.02% to 0.02%, a gain of 0.00 percentage points.

Ceribell Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Ceribell Inc No No No No
High-Confidence Competitors (2) 50% 50% 50% 0%
Similar-Size Competitors (10) 56% 78% 56% 57%
Similar Growth & Profitability (8) 0.00 % (0 of 8) 25.00 % (2 of 8) 0.00 % (0 of 8) 25.00 % (2 of 8)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q2 2026

100%market share
  • Ceribell Inc100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Ceribell Inc and its 0 tracked competitors.

See Ceribell Inc's full market share breakdown »

CBLL Stock Performance relative to its Competitors

CBLL Competitors (weighted) Percent change over the selected range

Ceribell Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
50%beat U.S.A. 500
Similar-Size
(5 of 10)
33.3%beat U.S.A. 500
Similar Growth & Profitability
(2 of 6)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Ceribell Inc 116.40 % Outperformed
Competitors combined (0) 40.4% 63.2%
High-Confidence Competitors (0) 40.4% 63.2%
Similar-Size Competitors (10) 40.4% 63.2%
Similar Growth & Profitability (6) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Ceribell Inc's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

CBLL Stock Performance relative to High-Confidence Competitors

CBLL High-Confidence Competitors (equal-weighted, 2) Percent change over the selected range

CBLL Stock Performance relative to Similar-Size Competitors

CBLL Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

CBLL Stock Performance relative to Similar Growth & Profitability Competitors

CBLL Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range

Ceribell Inc's Comment on Competition and Industry Peers

The company operates in the competitive market for EEG alternatives, primarily competing against conventional EEG systems commonly used in U.S. hospitals. Key competitors include Natus and Nihon Kohden, both of which have longer operating histories, greater brand recognition, larger market shares, more resources, stronger financial positions, and larger sales forces. The company also faces competition from firms developing rapid EEG systems for acute care and other settings such as home and ambulance use, including Natus and Nihon Kohden. Competitors may offer similar or superior products at more competitive prices and may be better positioned to serve customers.

Ceribell Inc's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Nihon Kohden Named by the company 85% 2022 to 2026 3
Vsee Health Inc Named by the company 85% 2022 to 2026 3
Natus Named by the company 85% 2022 to 2026 3
Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Ceribell Inc's named competitors require a Commercial License.

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.

Get the full CSIMarket dataset: Subscribe API License